(Q43127562)

14 November 2017

title

Cost-effectiveness of erlotinib versus docetaxel for second-line treatment of advanced non-small-cell lung cancer in the United Kingdom (English)

1 reference

14 November 2017

1 reference

1 reference

G Lewis

1

1 reference

14 November 2017

M Peake

2

1 reference

14 November 2017

R Aultman

3

1 reference

14 November 2017

M Gyldmark

4

1 reference

14 November 2017

L Morlotti

5

1 reference

14 November 2017

J Creeden

6

1 reference

14 November 2017

M de la Orden

7

1 reference

14 November 2017

language of work or name

1 reference

1 January 2010

1 reference

Journal of International Medical Research

14 November 2017

published in

1 reference

14 November 2017

volume

38

1 reference

14 November 2017

issue

1

1 reference

14 November 2017

page(s)

9-21

1 reference

Normative data and trends in quality of life from the Lung Cancer Symptom Scale (LCSS).

14 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1177%2F147323001003800102

Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323001003800102

Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323001003800102

Quality of life assessment of second-line docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy: results of a prospective, randomized phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323001003800102

Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323001003800102

Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323001003800102

The risk of febrile neutropenia in patients with non-small-cell lung cancer treated with docetaxel: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323001003800102

Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323001003800102

Epidermal growth factor-related peptides and their receptors in human malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323001003800102

HER1/EGFR-targeted agents: predicting the future for patients with unpredictable outcomes to therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323001003800102

Erlotinib in previously treated non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323001003800102

Salvage therapy for advanced non-small cell lung cancer: factors influencing treatment selection

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323001003800102

Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323001003800102

Epidermal growth factor receptor inhibitor-associated cutaneous toxicities: an evolving paradigm in clinical management.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323001003800102

A cost-effectiveness analysis of docetaxel in the second-line treatment of non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323001003800102

No study left behind: a network meta-analysis in non-small-cell lung cancer demonstrating the importance of considering all relevant data

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323001003800102

EQ-5D: a measure of health status from the EuroQol Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323001003800102

Is there a case for using visual analogue scale valuations in cost-utility analysis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323001003800102

Does NICE have a cost-effectiveness threshold and what other factors influence its decisions? A binary choice analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323001003800102

10.1177/147323001003800102

21 January 2018

Identifiers

DOI

1 reference

release_n33ju46ljneitgnuabddixl2le

14 November 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/n33ju46ljneitgnuabddixl2le

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference